Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:KRTX

Karuna Therapeutics (KRTX) Stock Price, News & Analysis

Karuna Therapeutics logo

About Karuna Therapeutics Stock (NASDAQ:KRTX)

Key Stats

Today's Range
$329.83
$329.83
50-Day Range
$313.97
$329.83
52-Week Range
$158.38
$329.99
Volume
5 shs
Average Volume
832,048 shs
Market Capitalization
$12.58 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$312.25
Consensus Rating
Hold

Company Overview

Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate includes KarXT, an oral modulator of muscarinic receptors for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of various peripheral tissues and dementia-related psychosis, including Alzheimer's disease. The company also focuses on developing other muscarinic-targeted drug candidates; and intends to develop lead candidature TRPC4/5 and KAR-2618 for the treatment of depressive disorder. Karuna Therapeutics, Inc. has a license agreement with Eli Lilly and Company, and Zai Lab (Shanghai) Co., Ltd; patent license agreement with PureTech Health LLC; and drug discovery partnership with Charles River Laboratories, as well as drug discovery collaboration with PsychoGenics, Inc. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

Receive KRTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Karuna Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

KRTX Stock News Headlines

Buffett’s Selling Out: Is Your 401(k) About to Get Wiped Out?
Let me share something important with you. Just a few weeks ago, Warren Buffett unloaded $932 million worth of bank stocks. He didn't do it on a whim—he knows something big is coming. The question is: Why aren't you taking action, too?
Bristol Myers to Purchase Karuna
See More Headlines

KRTX Stock Analysis - Frequently Asked Questions

Karuna Therapeutics, Inc. (NASDAQ:KRTX) issued its earnings results on Thursday, February, 22nd. The company reported ($3.01) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($2.65) by $0.36. The firm's revenue was down 100.0% on a year-over-year basis.

Karuna Therapeutics (KRTX) raised $70 million in an initial public offering on Friday, June 28th 2019. The company issued 4,400,000 shares at $15.00-$17.00 per share. Goldman Sachs, Citigroup and Wells Fargo Securities acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Based on aggregate information from My MarketBeat watchlists, some other companies that Karuna Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Tesla (TSLA), Palo Alto Networks (PANW), Salesforce (CRM) and Netflix (NFLX).

Company Calendar

Last Earnings
2/22/2024
Today
12/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:KRTX
Fax
N/A
Employees
339
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$312.25
High Stock Price Target
$330.00
Low Stock Price Target
$227.00
Potential Upside/Downside
-5.3%
Consensus Rating
Hold
Rating Score (0-4)
2.17
Research Coverage
12 Analysts

Profitability

Net Income
$-433,680,000.00
Pretax Margin
-66,209.48%

Debt

Sales & Book Value

Annual Sales
$654,000.00
Price / Sales
19,239.07
Book Value
$33.24 per share

Miscellaneous

Free Float
33,157,000
Market Cap
$12.58 billion
Optionable
Optionable
Beta
1.18
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

This page (NASDAQ:KRTX) was last updated on 12/9/2024 by MarketBeat.com Staff
From Our Partners